Valneva SE, a specialty vaccine company, engages in developing and commercializing vaccines for infectious diseases with unmet needs.
Excellent balance sheet with concerning outlook.
Share Price & News
How has Valneva's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: VLA's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: VLA exceeded the French Biotechs industry which returned -13.8% over the past year.
Return vs Market: VLA exceeded the French Market which returned -7.9% over the past year.
Price Volatility Vs. Market
How volatile is Valneva's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 year ago | Simply Wall StWhat Kind Of Shareholders Own Valneva SE (EPA:VLA)?
1 year ago | Simply Wall StValneva SE's (EPA:VLA) Path To Profitability
1 year ago | Simply Wall StDoes Valneva SE's (EPA:VLA) CEO Salary Compare Well With Others?
Is Valneva undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate VLA's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate VLA's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: VLA is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: VLA is unprofitable, so we can't compare its PE Ratio to the French market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate VLA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: VLA is overvalued based on its PB Ratio (3.5x) compared to the FR Biotechs industry average (3x).
How is Valneva forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: VLA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: VLA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: VLA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: VLA's revenue (15.5% per year) is forecast to grow faster than the French market (3.9% per year).
High Growth Revenue: VLA's revenue (15.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if VLA's Return on Equity is forecast to be high in 3 years time
How has Valneva performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: VLA is currently unprofitable.
Growing Profit Margin: VLA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: VLA is unprofitable, but has reduced losses over the past 5 years at a rate of 39.3% per year.
Accelerating Growth: Unable to compare VLA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: VLA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.5%).
Return on Equity
High ROE: VLA has a negative Return on Equity (-5.88%), as it is currently unprofitable.
How is Valneva's financial position?
Financial Position Analysis
Short Term Liabilities: VLA's short term assets (€142.7M) exceed its short term liabilities (€45.1M).
Long Term Liabilities: VLA's short term assets (€142.7M) exceed its long term liabilities (€98.3M).
Debt to Equity History and Analysis
Debt Level: VLA's debt to equity ratio (32%) is considered satisfactory.
Reducing Debt: VLA's debt to equity ratio has reduced from 38.5% to 32% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: VLA has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if VLA has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Valneva's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate VLA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate VLA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if VLA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if VLA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of VLA's dividend in 3 years as they are not forecast to pay a notable one for the French market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Thomas Lingelbach (56yo)
Mr. Thomas Lingelbach has been the Chief Executive Officer of Valneva SE since May 2013 and as its Chairman and Member of the Management Board since May 10, 2013. Mr. Lingelbach serves as a Managing Direct ...
CEO Compensation Analysis
Compensation vs Market: Thomas's total compensation ($USD1.67M) is above average for companies of similar size in the French market ($USD592.51K).
Compensation vs Earnings: Thomas's compensation has increased whilst the company is unprofitable.
|Chairman of the Management Board||7yrs||€1.50m||0.15% €526.4k|
|CFO & Member of Management Board||2.75yrs||€1.14m||0.043% €149.7k|
|General Counsel||3.08yrs||€964.87k||0.012% €40.6k|
|Chief Medical Officer & Member of Management Board||2.67yrs||€1.15m||0.021% €74.4k|
|Head of Investor Relations & Corporate Communications||no data||no data||no data|
|Human Resources Officer||no data||no data||no data|
|Head of Clinical Development||no data||no data||no data|
|Chairman of the Management Board of Valneva Sweden AB||no data||no data||no data|
|Head of Global Medical Affairs||no data||no data||no data|
Experienced Management: VLA's management team is considered experienced (2.8 years average tenure).
|Member of Supervisory Board||7.17yrs||€35.00k||0.023% €78.9k|
|Independent Member of Supervisory Board||7.17yrs||€30.00k||0.035% €121.1k|
|Member of Scientific Advisory Board||0.83yr||€2.92k||no data|
|Chairman of Supervisory Board||no data||€50.00k||0.28% €970.1k|
|Member of Scientific Advisory Board||0.50yr||no data||no data|
|Chair of Scientific Advisory Board||0.83yr||€2.92k||no data|
|Member of Scientific Advisory Board||0.50yr||no data||no data|
|Independent Member of Supervisory Board||7.17yrs||€30.00k||no data|
|Independent Member of Supervisory Board||2.92yrs||€30.00k||no data|
|Vice Chairperson of Supervisory Board||0.83yr||€45.00k||no data|
Experienced Board: VLA's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Valneva SE's company bio, employee growth, exchange listings and data sources
- Name: Valneva SE
- Ticker: VLA
- Exchange: ENXTPA
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: €346.420m
- Shares outstanding: 92.13m
- Website: https://www.valneva.com
Number of Employees
- Valneva SE
- Campus Bio-Ouest
- 6, Rue Alain Bombard
- Pays de la Loire
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|VLA||ENXTPA (Euronext Paris)||Yes||Common Shares||FR||EUR||Jun 2007|
|AYJ||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Jun 2007|
|0OB3||LSE (London Stock Exchange)||Yes||Common Shares||GB||EUR||Jun 2007|
|AYJ||XTRA (XETRA Trading Platform)||Yes||Common Shares||DE||EUR||Jun 2007|
|VLA||WBAG (Wiener Boerse AG)||Yes||Common Shares||AT||EUR||Jun 2007|
|INRL.F||OTCPK (Pink Sheets LLC)||Yes||Common Shares||US||USD||Jun 2007|
|VLA||SWX (SIX Swiss Exchange)||Yes||Common Shares||CH||CHF||Jun 2007|
|VLAP||ENXTPA (Euronext Paris)||PRF SHS EUR0.01||FR||EUR||May 2013|
|0QS6||LSE (London Stock Exchange)||PRF SHS EUR0.01||GB||EUR||May 2013|
|VNVL.F||OTCPK (Pink Sheets LLC)||PRF SHS EUR0.01||US||USD||May 2013|
|VLAPP||BATS-CHIXE (BATS 'Chi-X Europe')||PRF SHS EUR0.01||GB||EUR||May 2013|
Valneva SE, a specialty vaccine company, engages in developing and commercializing vaccines for infectious diseases with unmet needs. Its portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT indicated for the prevention of Japanese encephalitis; and DUKORAL indicated for the prevention of cholera and in some countries prevention of diarrhea caused by ETEC. The company has various vaccines in development, including a vaccine against Lyme disease. It has operations in Austria, Canada, France, Sweden, the United Kingdom, and the United States. Valneva SE and is based in Nantes, France.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/05/29 20:38|
|End of Day Share Price||2020/05/29 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.